Samsung Biologics Co Ltd
KRX:207940
Samsung Biologics Co Ltd
Accounts Receivables
Samsung Biologics Co Ltd
Accounts Receivables Peer Comparison
Competitive Accounts Receivables Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Samsung Biologics Co Ltd
KRX:207940
|
Accounts Receivables
₩760.4B
|
CAGR 3-Years
31%
|
CAGR 5-Years
50%
|
CAGR 10-Years
N/A
|
|
P
|
Peptron Inc
KOSDAQ:087010
|
Accounts Receivables
₩346.4m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Accounts Receivables
₩121.3B
|
CAGR 3-Years
53%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
F
|
FutureChem Co Ltd
KOSDAQ:220100
|
Accounts Receivables
₩2.9B
|
CAGR 3-Years
9%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Accounts Receivables
₩15.7B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
35%
|
C
|
Cellivery Therapeutics Inc
KOSDAQ:268600
|
Accounts Receivables
₩4.5B
|
CAGR 3-Years
128%
|
CAGR 5-Years
107%
|
CAGR 10-Years
N/A
|
See Also
What is Samsung Biologics Co Ltd's Accounts Receivables?
Accounts Receivables
760.4B
KRW
Based on the financial report for Mar 31, 2024, Samsung Biologics Co Ltd's Accounts Receivables amounts to 760.4B KRW.
What is Samsung Biologics Co Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
50%
Over the last year, the Accounts Receivables growth was 19%. The average annual Accounts Receivables growth rates for Samsung Biologics Co Ltd have been 31% over the past three years , 50% over the past five years .